Mereo BioPharma Group plc: Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung ...

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory diseaseOn option exercise, Sentynl will have the right to commercialize ...

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus") and Mereo BioPharma Group plc (Nasdaq: MREO) ("Mereo" ...

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory diseaseOn option exercise, Sentynl will have the right to commercialize ...
Gulf Today

Adnoc L&S posts record net profit of $951m in 2nd quarter

ADNOC Logistics and Services plc (ADNOC L&S), today reported record second quarter (Q2) and first-half (H1) 2026 results, surpassing market expectations ...
ZAWYA

ADNOC L&S posts record Q2 net profit of $951mln

ABU DHABI - ADNOC Logistics and Services plc (ADNOC L&S), today reported record second quarter (Q2) and first-half (H1) 2026 ...